ArticleJournal of gastrointestinal oncology2025
Evolving survival patterns in pancreatic adenocarcinoma: a 23-year retrospective observational analysis.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating survival patterns in pancreatic adenocarcinoma over two decades after introducing FOLFIRINOX.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic adenocarcinoma (PA) remains one of the most lethal malignancies. However, treatment options have expanded. Since 2011, FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and nab-paclitaxel plus gemcitabine have demonstrated superior outcomes over gemcitabine for advanced disease and have become standard chemotherapy regimens. This study aimed to analyze 23-year survival trends in PA at a Brazilian cancer center, focusing on comparisons between the pre- and post-FOLFIRINOX eras. Methods: This retrospective study analyzed patients diagnosed and treated at a large cancer center from 2000 to 2023, examining survival trends and changes in clinicopathological features and treatment across two 12-year periods: Period 1 (2000-2011), before FOLFIRINOX, and Period 2 (2012-2023), after FOLFIRINOX incorporation. The primary objective was to compare overall survival rates between the two time periods. The secondary objective was to evaluate changes in clinicopathological characteristics and treatment modalities. Results: A total of 1,078 patients were included in this analysis, with 274 patients in Period 1 and 804 patients in Period 2. The proportion of female patients increased in Period 2 (43.8% in Period 1 Conclusions: This 23-year analysis highlights the evolving treatment landscape and improved outcomes in PA with the introduction of more effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.